glp-1 drugs and crohn's disease Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations Practical Recommendations for Safe and Effective Use | Current Obesity Reports Relevance of Glucagon-Like Peptide 1

2.8% [4.7]

Whats the difference between metformin and Ozempic

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has revolutionized the treatment of Type 2 Diabetes Mellitus (T2DM)

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.

Per standard protocol, all patients had refrained from solid foods for at least 24 h and maintained nil per os for 12 h preceding their ESG

In addition to todays resource, please see and review the New York Times article, The Risks of Taking Drugs Like Ozempic When Youre Over 65: Medications that cause drastic weight loss raise specific concerns for older adults